Key Role of Combination Therapy and Nanodelivery in Triple Negative Breast Cancer

Abstract

Cancer involves the effects of cancer cells with the tumor microenvironment, including non-cancer cells and cytokines, and the preferred treatment option is to target TME rather than directly targeting cancer cells. Triple-negative breast cancer has a unique tumor microenvironment, and immunotherapy targeting PD-1 can restore T cell immune function, but immunotherapy alone is ineffective in most patients and is often used in combination with other treatments. Since triple-negative breast cancer is sensitive to paclitaxel, combined chemotherapy can effectively regulate the tumor microenvironment and cause cancer cell death. By limiting the dose of paclitaxel, it can be used in combination with nanotechnology to regulate the combination therapy. This paper summarizes the potential of spatial transcriptome, single-cell RNA sequencing, and immunogenic cell immunogenic mortality estimation to investigate the efficacy of paclitaxel and anti-drug combinations in the treatment of various types of breast cancer in the third negative group, and analyzes examples of nanotechnology applications in the field of thiothiols to significantly improve the tumor microenvironment. Paclitaxel combined with anti-PD-1 therapy can regulate the tumor microenvironment, and drug transport and chemical repair are the main mechanisms.